Junhao Wen,Zhijian Yang,Ilya M. Nasrallah,Yuhan Cui,Guray Erus,Dhivya Srinivasan,Ahmed Abdulkadir,Elizabeth Mamourian,Ioanna Skampardoni,Gyujoon Hwang,Ashish Singh,Mark Bergman,Jingxuan Bao,Erdem Varol,Zhen Zhou,Aleix Boquet-Pujadas,Jiong Chen,Arthur W. Toga,Andrew J. Saykin,Timothy J. Hohman,Paul M. Thompson,Sylvia Villeneuve,Randy Gollub,Aristeidis Sotiras,Katharina Wittfeld,Hans J. Grabe,Duygu Tosun,Murat Bilgel,Yang An,Daniel S. Marcus,Pamela LaMontagne,Tammie L. Benzinger,Susan R. Heckbert,Thomas R. Austin,Lenore J. Launer,Mark Espeland,Colin L Masters,Paul Maruff,Jurgen Fripp,Sterling C. Johnson,John C. Morris,Marilyn S. Albert,R. Nick Bryan,Susan M. Resnick,Luigi Ferrucci,Yong Fan,Mohamad Habes,David Wolk,Li Shen,Haochang Shou,Christos Davatzikos

Abstract:Alzheimer’s disease (AD) is associated with heterogeneous atrophy patterns. We employed a semi-supervised clustering technique known as Surreal-GAN, through which we identified two dominant dimensions of brain atrophy in symptomatic mild cognitive impairment (MCI) and AD patients: the “diffuse-AD” (R1) dimension shows widespread brain atrophy, and the “MTL-AD” (R2) dimension displays focal medial temporal lobe (MTL) atrophy. Critically, only R2 was associated with widely known sporadic AD genetic risk factors (e.g., APOE ε4 ) in MCI and AD patients at baseline. We then independently detected the presence of the two dimensions in the early stages by deploying the trained model in the general population and two cognitively unimpaired cohorts of asymptomatic participants. In the general population, genome-wide association studies found 77 genes unrelated to APOE differentially associated with R1 and R2. Functional analyses revealed that these genes were overrepresented in differentially expressed gene sets in organs beyond the brain (R1 and R2), including the heart (R1) and the pituitary gland, muscle, and kidney (R2). These genes were enriched in biological pathways implicated in dendritic cells (R2), macrophage functions (R1), and cancer (R1 and R2). Several of them were “druggable genes” for cancer (R1), inflammation (R1), cardiovascular diseases (R1), and diseases of the nervous system (R2). The longitudinal progression showed that APOE ε4 , amyloid, and tau were associated with R2 at early asymptomatic stages, but this longitudinal association occurs only at late symptomatic stages in R1. Our findings deepen our understanding of the multifaceted pathogenesis of AD beyond the brain. In early asymptomatic stages, the two dimensions are associated with diverse pathological mechanisms, including cardiovascular diseases, inflammation, and hormonal dysfunction – driven by genes different from APOE – which may collectively contribute to the early pathogenesis of AD.### Competing Interest StatementDAW served as Site PI for studies by Biogen, Merck, and Eli Lilly Avid. He has received consulting fees from GE Healthcare and Neuronix. He is on the DSMB for a trial sponsored by Functional Neuromodulation. AJS receives support from multiple NIH grants, P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177. He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, in kind contribution of PET tracer precursor, Bayer Oncology Scientific Advisory Board, Eisai Scientific Advisory Board, Siemens Medical Solutions USA, Inc. Dementia Advisory Board, Springer-Nature Publishing Editorial Office Support as Editor in Chief, Brain Imaging, and Behavior. ME receives support from multiple NIH grants, the Alzheimers Association, and the Alzheimer Therapeutic Research Institute. HJG has received travel grants and speaker honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag as well as research funding from Fresenius Medical Care. HJG had personal contracts approved by the university administration for speaker honoraria and one IIT with Fresenius Medical Care. AA was supported by grants 191026 and 206795 from the Swiss National Science Foundation

Personalized whole-brain neural mass models reveal combined Aβ and tau hyperexcitable influences in Alzheimer's disease

In-vivo neuronal dysfunction by Aβ and tau overlaps with brain-wide inflammatory mechanisms in Alzheimer's disease

Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease

A Multiscale Closed-Loop Neurotoxicity Model of Alzheimer's Disease Progression Explains Functional Connectivity Alterations

Synergistic association of Aβ and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults

[In Vitro Pathological Model of Alzheimer's Disease Based on Neuronal Network Chip and Its Real-Time Dynamic Analysis].

A computational model of Alzheimer's disease at the nano, micro, and macroscales

A human neuronal model of sporadic Alzheimer’s disease induced by downregulation shows Aβ aggregation, tau hyperphosphorylation and functional network impairment

Genetic, Clinical Underpinnings of Brain Change along Two Neuroanatomical Dimensions of Clinically-defined Alzheimer’s Disease

Functional Neurophysiological Biomarkers of Early‐Stage Alzheimer’s Disease: An Experimental Perspective of Network Hyperexcitability in Disease Progression and Pharmacological Interventions

Uncovering the System Vulnerability and Criticality of Human Brain under Dynamical Neuropathological Events in Alzheimer's Disease

Subcellular proteomics and iPSC modeling uncover reversible mechanisms of axonal pathology in Alzheimer's disease

Global amyloid burden enhances network efficiency of tau propagation in the brain

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease

Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms

Modeling neuropathology of Alzheimer’s disease in aged patient‐derived neurons through 3D direct neuronal reprogramming

A Network-Guided Reaction-Diffusion Model of AT[N] Biomarkers in Alzheimer's Disease

Brain network fingerprints of Alzheimer's disease risk factors in mouse models with humanized APOE alleles

Meta-Analysis in Transgenic Alzheimer's Disease Mouse Models Reveals Opposite Brain Network Effects of Amyloid-β and Phosphorylated Tau Proteins

A human induced pluripotent stem cell-derived cortical neuron human-on-a chip system to study Aβ42 and tau-induced pathophysiological effects on long-term potentiation

Multi-omic ADNI CSF and plasma data integration identifies distinct metabolic transitions in disease progression in Alzheimer's Disease